PHII-95 Randomized, Phase II Trial of AZD6244 Alone and AZD6244 plus Temsirolimus for Soft-Tissue Sarcomas.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2016
At a glance
- Drugs Selumetinib (Primary) ; Temsirolimus
- Indications Leiomyosarcoma; Soft tissue sarcoma
- Focus Therapeutic Use
- 23 Apr 2015 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 03 Jun 2014 Primary endpoint 'Progression-free-survival-duration' has not been met.
- 03 Jun 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.